Gene Bridges licenses recombineering technology to Chugai Pharmaceutical
Gene Bridges, a German recombineering specialist, and Chugai Pharmaceutical of Tokyo, Japan have expanded their 2005 agreement for the use of Gene Bridges" Red/ET recombination technology.
Gene Bridges, a German recombineering specialist, and Chugai Pharmaceutical of Tokyo, Japan have expanded their 2005 agreement for the use of Gene Bridges" Red/ET recombination technology.
The Red/ET recombination technology, patented in Japan as a novel DNA cloning method, is used to generate targeting vectors or modify E. coli chromosomes.
"Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide," said Gary Stevens, ceo of Gene Bridges. "Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese pharmaceutical company, which found the existing agreement worthwhile expanding."
Recombineering with Red/ET allows cloning, sub-cloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
Funakoshi represents Gene Bridges in Japan.
Gene Bridges
T +49 6221 13708 10